NIH #5R01CA276268-03
Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer
- Amount
- $562K
- Period
- 2023-01-01 → 2027-12-31
- PIs
- 1
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
Pancreatic and Hepatic Oncology Research · Oncology
4 total · 4 active
NIH #5R01CA276268-03
Awarded at DANA-FARBER CANCER INST
NIH #1R01CA276268-01
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA276268-04
Awarded at DANA-FARBER CANCER INST
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Supplemental Table 1 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
2026-06-17
Supplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
2026-06-17
2026-06-17
Supplemental Table 6 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
2026-06-17
2026-06-17
2026-06-17
Supplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
2026-06-17
2026-06-17
Supplemental Table 3 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
Supplemental Table 4 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
Supplemental Table 9 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
2026-06-17
Supplemental Table 8 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
2026-06-17
Supplemental Table 5 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2026-06-17
2026-06-17